Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 29Gynecologic 6Genitourinary 5Sarcoma 4Thoracic 2Other solid neoplasm 2Head & Neck 2CNS 2Tumor-Agnostic 1Lymphoid 1Dermatologic 1

Conditions

Resectable MMR-deficient Solid Tumors 1Advanced Solid Tumor 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × balstilimab × Other solid neoplasm × Clear all
NCT06279130 2026-03-05

NEOASIS

The Netherlands Cancer Institute

Phase 2/3 Recruiting
133 enrolled
Other solid neoplasm

Resectable MMR-deficient Solid Tumors

NCT05377528 2025-04-30

Study of AGEN1571 in Participants With Advanced Solid Tumors

Agenus Inc.

Phase 1 Completed
22 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡